WHY WOULD ONE INVEST IN RAINBOW BIOSCIENCES (OTCBB: RBCC)?
-RBCC has CLAIMED to acquired a new equity interest in Nano3D Biosciences, Inc. (n3D) - yet the financials say otherwise.
-n3D's nanoparticle technology is claimed that it could completely revolutionize cell research - and RBCC falsely states in its press releases that it has a Joint Venture - which would imply sharing of revenues - none of which is true as there is no such JV indicated in the financials.
-RBCC is NOT spearheading ANY innovative scientific and medical breakthroughs. It has NO bioscience assets, NO R&D budget, NO employees with any bioscience experience and has NO revenues in the $84.6 billion global biotech industry.
-U.S. biotech companies raised $25 billion in 2010--a 15-percent jump over the previous year's investment total, according to Ernst & Young. RBCC has ZERO bioscience revenues and ZERO JV's or deals completed.
-RBCC is NOT joining the ranks of bioscience companies like Puma-a company that recently announced a private placement of 14.7 million shares of its common stock to investors, resulting in proceeds of $55 million because it simply does NOT have the MONEY, ASSETS, EXPERTISE, KNOWLEDGE, OR CAPABILITY TO EXECUTE.
